DiaMedica Therapeutics Stock Forecast, Price & News

-0.54 (-5.89 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume122,526 shs
Average Volume127,791 shs
Market Capitalization$162.12 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DiaMedica Therapeutics logo

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.16 out of 5 stars

Medical Sector

1014th out of 2,100 stocks

Pharmaceutical Preparations Industry

494th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

Is DiaMedica Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DiaMedica Therapeutics stock.
View analyst ratings for DiaMedica Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than DiaMedica Therapeutics?

Wall Street analysts have given DiaMedica Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DiaMedica Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for DiaMedica Therapeutics

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.04.
View DiaMedica Therapeutics' earnings history

How has DiaMedica Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DMAC stock has increased by 115.8% and is now trading at $8.63.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DMAC?

5 Wall Street analysts have issued twelve-month price objectives for DiaMedica Therapeutics' stock. Their forecasts range from $14.00 to $38.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $23.83 in the next year. This suggests a possible upside of 176.2% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Dietrich John Pauls M.B.A., MBA, Pres, CEO & Director (Age 50, Pay $687.58k)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 56, Pay $370.16k)
  • Dr. Harry W. Alcorn Jr., Chief Medical Officer (Age 65, Pay $389.93k)
  • Dr. Edward G. Calamai, Consulting Head of Manufacturing

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Corriente Advisors LLC (4.63%), Point72 Asset Management L.P. (2.94%), Granite Point Capital Management L.P. (0.98%), Renaissance Technologies LLC (0.81%), Geode Capital Management LLC (0.68%) and EAM Investors LLC (0.58%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends for DiaMedica Therapeutics

Which institutional investors are selling DiaMedica Therapeutics stock?

DMAC stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P., Point72 Asset Management L.P., Northern Trust Corp, Bank of New York Mellon Corp, and EAM Investors LLC.
View insider buying and selling activity for DiaMedica Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying DiaMedica Therapeutics stock?

DMAC stock was bought by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, Millennium Management LLC, Geode Capital Management LLC, Bank of Montreal Can, Citadel Advisors LLC, and Citadel Advisors LLC. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen.
View insider buying and selling activity for DiaMedica Therapeutics
or or view top insider-buying stocks.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $8.63.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics has a market capitalization of $162.12 million and generates $500,000.00 in revenue each year. The company earns $-12,290,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does DiaMedica Therapeutics have?

DiaMedica Therapeutics employs 10 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is

Where are DiaMedica Therapeutics' headquarters?

DiaMedica Therapeutics is headquartered at 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.